iLoF Secures $5m to Expand its Digital Library of Biomarkers 📰
Our cloud-based library of optical fingerprints, powered by photonics and AI, provides non-invasive tracking, screening and stratification for drug discovery, adapted to each clinical trial needs.
Efficient. Flexible. Patient-centric.
Minimally Invasive
Requires only microlitres of blood
Agnostic
Allows for label free flexibility on targets
Rapid
Takes <10 seconds from start to finish
Low cost
Requires no consumables, only Light and AI
Featured By
How can we help?
Our blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or degree of progression. The iLoF Platform offers:
40% cost savings
70% reduction of time spent on screenings
A non-invasive process for patient convenience
A pool of more qualified candidates, improving trial outcomes
Paving the way for personalised medicine
We believe the possibilities for the iLoF Platform are endless. Keeping Alzheimer’s as a leading focus, we are building out our virtual fingerprint library and plan to bring the power of this platform to other diseases
Alzheimer
Early and differential screening of dementia patients with Alzheimer’s Disease
COVID-19
Forecasting clinical outcomes and predicting severity of symptoms of Covid-19 patients
Ovarian Cancer
Stratifying cancer subtypes allowing for design and delivery of tailored treatments
Investors and Partners
Awards
GET IN TOUCH
United Kingdom
124 City Road
EC1V 2NX London
(+44) 01865 679064
United States
260 East Main Street, Suite 6380
New York 14604
(+1) 617 4888673
Portugal
Founders Founders Porto Oriental
Rua de Godim, 389 – 1st floor
4300-240 Porto
(+351) 225 370 847
Privacy Policy
